NYSEARCA:XPH SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News $66.09 -0.31 (-0.47%) Closing price 04:10 PM EasternExtended Trading$66.11 +0.02 (+0.03%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest About SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XPH alerts:Sign Up Key Stats Today's Range$65.70▼$66.6950-Day Range$66.23▼$74.0652-Week Range$46.24▼$74.35Volume65,498 shsAverage Volume100,218 shsMarket Capitalization$545.24 millionAssets Under Management$548.54 millionDividend Yield0.41%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF Overview SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor. Read More SPDR S&P Pharmaceuticals ETF ExpensesTypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.55%0.57%0.50%0.53%Other Expenses0.00%0.52%0.53%0.60%0.54%Total Expense0.35%0.76%0.75%0.75%0.73%Fee Waiver0.00%-0.85%-0.67%-0.78%-0.68%Net Expense0.35%0.58%0.63%0.57%0.60% Receive XPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XPH ETF News HeadlinesSPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0416September 21, 2026 | msn.comIXJ vs XPH: Global Healthcare ETF or Pharma Focus?September 11, 2026 | fool.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 25 at 1:00 AM | Chaikin Analytics (Ad)Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPHSeptember 10, 2026 | finance.yahoo.comXPH: Dividendenhistorie, Rendite und Ex-Dividenden-TagAugust 23, 2026 | de.investing.comXPH vs PJP: Which Pharma ETF Offers Better ValueAugust 17, 2026 | fool.comSee More Headlines XPH ETF - Frequently Asked Questions How have XPH shares performed this year? SPDR S&P Pharmaceuticals ETF's stock was trading at $56.01 at the beginning of the year. Since then, XPH stock has increased by 18.0% and is now trading at $66.09. Who are SPDR S&P Pharmaceuticals ETF's major shareholders? SPDR S&P Pharmaceuticals ETF's top institutional investors include Envestnet Asset Management Inc. (2.59%), Envestnet Portfolio Solutions Inc. (2.11%), Integrated Wealth Concepts LLC (0.68%) and SVB Wealth LLC (0.59%). How do I buy shares of SPDR S&P Pharmaceuticals ETF? Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Pharmaceuticals ETF investors own include NVIDIA (NVDA), Pfizer (PFE), Adobe (ADBE), Applied Materials (AMAT), Chevron (CVX), JPMorgan Chase & Co. (JPM) and Meta Platforms (META). Fund Details IssuerSSgA Fund NameSPDR S&P Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XPH Inception Date6/19/2006 Fund ManagerMichael Feehily, Karl Schneider, Keith Richardson Webwww.spdrs.com Phone+1-617-6644738Fund Focus Asset ClassEquity BenchmarkS&P Pharmaceuticals Select Industry Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings89 Fund Statistics Assets Under Management$548.54 million Average Daily Volume$179.05 thousand Discount/Premium-0.09% Administrator, Advisor and Custodian AdministratorState Street Global Advisors Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Options OptionableN/A Short Interest624,905 shs Miscellaneous Outstanding Shares8,250,000Beta0.59 Creation Unit50,000 Creation Fee$250.00 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report Top 10 XPH HoldingsAmneal Pharmaceuticals (NASDAQ:AMRX)Holding Weight: 2.21%Xeris Biopharma (NASDAQ:XERS)Holding Weight: 2.16%Veradermics (NYSE:MANE)Holding Weight: 2.14%ANI Pharmaceuticals (NASDAQ:ANIP)Holding Weight: 2.11%Definium Therapeutics (NASDAQ:DFTX)Holding Weight: 1.96%Eli Lilly and Company (NYSE:LLY)Holding Weight: 1.96%Viatris (NASDAQ:VTRS)Holding Weight: 1.96%Edgewise Therapeutics (NASDAQ:EWTX)Holding Weight: 1.95%Indivior (NASDAQ:INDV)Holding Weight: 1.93%Supernus Pharmaceuticals (NASDAQ:SUPN)Holding Weight: 1.93%Full Holdings DetailsXPH Sector ExposureXPH Industry Exposure This page (NYSEARCA:XPH) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
